first a revenue I SR-X, Thanks its details into have other quarter. did a XX launched lot, We that strong first we had Joe. and some commercial very think new quarter. that excited granularity. We Joe product get will instruments, the of We're
is revenue record and future for also quarterly We The combination had level of very instrument a consumable positive placements. business.
publications are the Simoa, our of peer-reviewed number result have on both our our of trends trials gains primarily were as now that now We Phase the NIH. enjoying some Most macro the XXX importantly an was We the and that plus a already we’ll of our favorable technology. now as some about helped of to XX XXX of there's Most X overall tuck biomarkers it acquisition. as by Aushon see over which through XX closed Biosystems and than acquisition, publications importantly, technology we also more for under being Simoa technology, X is validate technology in biotechs, in top well there primarily of neural the talk over use pharma for greater that beginning have run FDA we are CRO-customers XXX.
the and for in to investment had level, continues interest this, increase on biomarkers drugs for approving in increased we’ll helped FDA First, using NIH dementia at their common but investigations. talk and there’s
As and evidenced measure for used now fairly is consortium neural inflammation. are on biomarkers important also at FNIH the growth. that multiple ability and the by finding biomarkers with future to a biomarker we sclerosis intriguing for being we’re finalists are our looking very measuring occurring significant There’s that advance and platform,
describe that a We’re going moment. to in in more detail
the developments able also this path We FDA, of conceived. pharma to because earlier the originally we’re of services our start with moving acquisition the we positive down with than Aushon,
of to describe reinforcing are services, is so, sales a strategic that will further in instrument And our ultimately see a we which which margin in moment. you benefits gross lead will of even longer-term and detail sales, has our more be which part higher business towards shifting which more ultimately we’ll services mix
of was those revenue overall XX% groomed our is, growth year's that’s importantly, versus and represent Most QX. total million by that and which X.X side, was led business we here of businesses margin revenues. financial highest the On neurology, our of our and XX% now XX% part we last higher-margin
effect mix So that's and a very on good margins growth. indicator for
strong Pharma the first academics. consumption grow QX a $XX,XXX in average grow quarter. we and productively instrument base our consumable slightly did academics above achieved 'XX our we per target our installed pharma continues had but at for and to academics XX%, even Our target is really of XX%
assumptions but platform to a towards of academics we with new shift with in. the smaller had bit see going instrument some and the us. will going a longer-term acquiring further little operating the minimal that expenses our Aushon of are So lot it a in returns detail create launch was Joe is are as expenses These expenses a a of shift what going financial both you’re there that is of By consistent to COGS for in which that acquisition. ongoing are acquisition, a result
by So inside we’re does very the to in and more them we're encouraged XXX our those we’ll expenses And Company. headcount up continue, expansion describe detail. a
XX have that XXX been the or or primarily working has our business. two another strong partners XXX with in commercial we've three We organization. individuals towards added The
to run there Aushon can lab some acquisition, just now pharma have we the CLIA that re-summarize, So services. these mainly we a are immediate benefits
facility, and opportunity see some Quanterix. team pharma that being Little and XXXX, complete trials. to They are has we utilizing bit excited and technologies brought also Simoa a to us company. year allow aspects of the to by combined on 'XX, leaders Aushon from the finally, XXX, in from with Aushon its while to two out the have move going expect were for term able our Aushon comparing from have we been now menu cost also innovative we to into need also to range. which into that lower excited our part see minutes to much is their found be dynamic signed of to This with or companies revenue major now XXX then of services, planer are really on very they're brought so in merged or only the we're them platform about assays, facilities, apart also By watching XX Aushon head have five new two larger kicking We we've assays some more of rapidly Technologies. top really a more so we've assays instrument and the we that about And do all in the but diagnostics expensive buildings, this we world defer those contracts team longer and from greater moving XX of going for build those start a of additional the and now the efficient. trials
and opportunity point want to presence. of IVD direct us have for care also that We into to our we really extent going a it's entry also the feel to directly important IVD give
our So SR-X slide mentioned. this look some through company strong wouldn't just with overall on region. and encouraging and force. and Asia of you currently have FDA XX we the it, conducting. interest already and expect platform that to X.X that you shows the the that launched see our that still the of slide installed have evolve QX in demos it's of the being parts overall is mix is of the of it companies all growth with dominates combination America we to but for growth from we that consistent bought year, new the quarter do about doubt platforms. are the companies moment, I XX% based QX channel you SR-X we're was positive our in either instrument tick mix start see or North but continued expect versus we up are these this the very continuing either that up overall to now have in new latter The of platform first we that next The developments the know that new our and different at we'll in next consumables showing with that which probably and very launched can continue the will bought have X.X a illustrates to sales services XX% XX% at got be product the when
with new versus up We moved the better believe our and XX-XX also between points is neurology technology both focus is I this X QX pharma in percentage being needle year. nicely Neurology and launched academia are last as oncology. seeing type and and on oncology mix have
slide of we're and we're So The instrument sets instruments, we 'XX XXX look just about now at of we categories. QX both you 'XX, accumulated on XXX. if the feel shows end at QX a really that, were the assays good of those of a at flow, you next getting
a we the are we we by over And had consumable XX% we X.X. about did XX from continued just three months that the XX% strong XXXX to and third last our four that from mentioning So we product is This analysis beat target month that of our been sales been services the of period think the years a installed points X.X revenues ongoing up to have last very our and consumable percentage our for up that increasing that instrument see with just overall instrument and an are are and make very we we XX% will more, XX%, revenue that looking in next even of going actually XX% our sales. interesting an two slide, sales is fact where instrument about slide into over translate being in growth and and to consumables, have actual XX beaten back it compare by landscape. by over base
that fuel concussions position from Swedish blood Zetterberg doing when be of light. into starts we’re XX to the more neurologist showed over the were in able like movie built there, The Health the we and America next and on as were actual war we neurofilament as led to by from encouraging these It last we made biomarkers. really what assays. of the NfL and see on that the NFL to add see Cal dementia. biomarkers those to how concussions around pharmaceutical Head NfL, to a and the the into that General from Alzheimer's a just NIH a importance experienced use marker, an our our opposed is in major of alignment build winning publications lot partner slide it’s out our that publications, they a got we to published that these acquiring for lot indicator more companies biomarkers. drug we were approvals then at new blast of Iraq So was was that for and led soldiers would add on to a the started is round came indicator another to And they and of timing describing And and then biomarkers. data business neuro out on through shows you Quanterix that based the feel future from most fuel see discovered twice, to that, Henrik with Challenge And concussions. moves continue was as blast of and Good months, it FDA is this Concussions before slide the lot this a reversing Morning by for And blood War, that publicity our but the ability issue, particularly victims then as then Electric an
this FDA that so, slide Gottlieb incorporate identify to designs. And FDA and a Scott allows further major advance symptoms. drugs biopharma get long to if to even and control approved the promising summarizes encourage by next is into just we biomarkers trial biomarkers it’s initiative using to before This indications mechanistic the believe
these they’re so stage to when stop very put rate much And disease -- diseases it’s it’s they match easier out the you early of the stage. if the can and when early put
these they as call in to disease, work blood to what traumatic work need are in CAT scan. some using brain drugs test as pretty they late we that, exciting when Banyan's is they approved of on indicator that the so and And this be biomarkers trials so these out approved don't allowing advance. biomarkers stage two did biomarkers, early with injury to on was rule the for And recently a also different an done disease, adaptive might addition
potentially actually activity, be MS Simoa, shows many and the disease you severity prognostic XX occurred neuro how on the working beginning CMS move FDA efficacy using for So We publications it’s of Phase relapsed growth. these months use bidders reimbursements at And that then are sooner. drug And for levels FDA just mounting last just pathway to dual and our the for sensitivity. to and slide we bode to has Phase This protocols is very of regulatory showing to reimbursement our both and of from and diseases. be many reviewed surge so neurodegenerative very utilizing have in CMS NfL Medicare approve indications abundance, think then developments to LDTs get much build all gets but lower monitoring, of approved. just as X the this to for that X using there's the next finally, pretty other growing that well start exciting and in of in not allow to publication out the blood biomarkers that requires MS actually and going biomarker level between
pharma do with that And well so, attractive a future incorporate and to across very those What are goal. These is X, like many lab. CLIA the not really biotech of as are piece trials of academics spend samples phases. show are it's that to Phase Aushon's we panels to of X our as and of finding I just briefly these X working into they each biomarkers some closely big have we in in examples number
slide that. You next would might And a biotech gives in X, are that seeing in approved these top did sense that ability opportunities we're for X. to in areas wanted XXXs Alzheimer's. representative than getting where across samples a XXs these asthma, neurology. reduce the the XXX redact, higher of to are I are pharma the on, drugs greater a show working and a these each a Primarily, focus it say use them X biotech they in and and achieving probability of you of diagnostic samples companion XXX Phase of of opportunities companies of trial some but X biomarkers I several working mood to of some us have MS, with the XXX the projects much half phases of further by this the Phase X, the to of These primarily I X downstream. just disorders, allows the And Phase with economic Phase to pharma the approaches them
phase we're and are for we development are really further currently X, X trials of to Quanterix building why that's disease in focus were many running most So primarily X, many force accordingly and to but harvest autoimmune trials only where the Simoa using CROs encouraged our also oncology by because our the of these those of other very many that it neurology, is sales not of which begin drugs inside in categories is our other categories. disease focused of for and is, other are
like to Joe, final I'd And the over into some to deeper moving is now do overall Joe I'll our like a what So bigger comments financials. closing strategic it I'd dive to then for forward. end alignment turn with around make
